Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics� SEC disclosures aren’t just numbers—they detail how the company’s EEV� platform may unlock intracellular targets that traditional medicines miss. Yet decoding R&D expense lines, clinical trial updates, and collaboration milestones in a 300-page 10-K can feel overwhelming. If you’ve searched “Entrada Therapeutics SEC filings explained simply� or wondered how recent 8-K material events tie to Duchenne muscular dystrophy studies, you’re not alone.
Stock Titan bridges that gap. Our AI parses every Entrada Therapeutics quarterly earnings report 10-Q filing, flags cash-runway shifts, and converts scientific jargon into clear language. Receive Entrada Therapeutics Form 4 insider transactions real-time alerts to track when executives buy or sell shares. Need context for a sudden shelf registration? The platform links S-3 details to potential capital raises and provides concise, expert commentary. From the annual report 10-K simplified to each proxy statement executive compensation, you’ll find form-specific summaries, keyword search, and side-by-side comparisons � all updated the moment EDGAR posts.
Use these insights to:
- Monitor Entrada Therapeutics insider trading Form 4 transactions before key readouts
- Compare trial spending across quarters with our “cash used in operations� trend tool
- Spot risk-factor changes the instant they appear in an 8-K
Dipal Doshi, who serves as CEO and a director of Entrada Therapeutics, Inc. (TRDA), reported a sale of 8,723 shares of common stock on 09/02/2025 to cover tax withholding obligations arising from vested restricted stock units. The sale price shown is a weighted average of $5.4302 with reported trade prices ranging from $5.36 to $5.58. After this transaction, the reporting person beneficially owned 415,664 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.
Entrada Therapeutics insider sale to cover RSU taxes The filing shows Nathan J. Dowden, President & COO of Entrada Therapeutics (TRDA), reported a sale of 1,746 shares of common stock on 09/02/2025 at a weighted average price of $5.4302. After the sale he beneficially owned 179,059 shares. The filing states the sale was to satisfy tax withholding obligations arising from vested restricted stock units and was executed in multiple transactions at prices ranging $5.36 to $5.58.
Sethuraman Natarajan, an officer at Entrada Therapeutics, Inc. (TRDA), reported a sale of 1,760 shares of the company's common stock on 09/02/2025 to satisfy tax withholding obligations from vested restricted stock units. The filing shows a weighted-average sale price of $5.4302, with individual trade prices ranging from $5.36 to $5.58. After the reported disposition, the reporting person beneficially owns 197,899 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025. The filing is a routine insider report documenting a tax-withholding sale tied to RSU vesting and does not state any other transactions or derivative holdings.
Entrada Therapeutics CFO Kory James sold 1,734 shares on 09/02/2025 to cover tax withholding arising from RSU vesting. The weighted-average price for the sales was $5.4302, with transaction prices reported between $5.36 and $5.58. After the sale, the reporting person beneficially owned 118,936 shares, held directly. The Form 4 was filed indicating the sale was to satisfy withholding obligations tied to previously granted restricted stock units.
Janus Henderson Group plc reports beneficial ownership of 1,521,281 shares of Entrada Therapeutics common stock, representing 4.0% of the class. The filing states Janus Henderson has no sole voting or dispositive power and shared voting and dispositive power over all reported shares.
The filing identifies certain indirect subsidiaries (including JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Entrada Therapeutics, Inc. (Form 10-Q) � quarter ended June 30, 2025. The company reported $72.5M cash and cash equivalents and $281.5M marketable securities (total $354.0M) and total assets of $448.8M as of June 30, 2025. Total liabilities were $69.3M and accumulated deficit was $189.8M. Shares outstanding: 38,033,970 as of June 30, 2025 (38,037,079 as of July 31, 2025).
Operational and financial results: collaboration revenue was $1.95M for Q2 2025 and $22.51M for the six months ended June 30, 2025 (versus $94.69M and $153.81M in the comparable 2024 periods). R&D expense was $37.88M in Q2 2025 and $69.95M for six months; G&A expense was $10.92M and $21.20M, respectively. Net loss: $43.10M for the quarter and $60.45M for six months (basic net loss per share Q2: $1.04; six months: $1.47).
Corporate developments: first patient dosed in ELEVATE-44-201 and ELEVATE-45-201 initiated; company expects to file for ENTR-601-50 in Q4 2025. Vertex collaboration revenue recognition included a cumulative catch-up adjustment of $12.3M during H1 2025 and the remaining transaction price allocated to unsatisfied obligations was $0.9M at June 30, 2025. The company implemented a ~20% workforce reduction in April 2025 with a related charge of $1.9M. Management states liquidity is sufficient to fund operations into the second quarter of 2027.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
